Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-beta T-cell therapy combined with immune checkpoint inhibitor for advanced or relapsed malignant tumors
jRCTc031190101Completed
- Start
- Jun 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial in cancer. Primary endpoint: Efficacy. Started Jun 2020; status: completed.
02
Conditions
cancer
Beyond the preview
Go deeper on jRCTc031190101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTc031190101.